View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsTradeUP Acquisition 配当と自社株買い配当金 基準チェック /06TradeUP Acquisition配当金を支払った記録がありません。主要情報n/a配当利回り178.3%バイバック利回り総株主利回り178.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella.決済の安定と成長配当データの取得安定した配当: UPTDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: UPTDの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場TradeUP Acquisition 配当利回り対市場UPTD 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (UPTD)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Capital Markets)2.1%アナリスト予想 (UPTD) (最長3年)n/a注目すべき配当: UPTDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: UPTDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: UPTDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: UPTDが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/04 06:55終値2023/09/29 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TradeUP Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).
お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella.